ASHP Statement on the Pharmacist’s Role in Clinical Pharmacogenomics

Haidar, Cyrine-Eliana; Petry, Natasha; Oxencis, Carolyn; Douglas, Janine; Hoffman, James M.

doi:10.1093/ajhp/zxab339

Cited by 52 publications

(34 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The importance of pharmacists' involvement in PGx is currently being highlighted by a diversity of initiatives. In a statement draft on the pharmacist's role in clinical PGX, the American Society of Health-System Pharmacists (ASHP) defined the pharmacists' possible responsibilities concerning PGx services (Haidar et al, 2022). Moreover, the American Pharmacists Association has also acknowledged the pharmacists' capacity to incorporate PGx into drug therapy management, while the American College of Clinical Pharmacy and the American Association of Colleges of Pharmacy host PGx practitioner and educator groups (Owusu-Obeng et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

“…As point-of-care providers and drug experts, pharmacists are uniquely positioned in the healthcare system to appreciate the necessity of ordering a PGx test and to interpret the results for an optimal adjustment of patient drug therapy (Haidar et al, 2022). Therefore, pharmacists could play an important role in the integration of genotype-guided drug therapy into routine practice.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nation-Wide Survey Assessing the Knowledge and Attitudes of Romanian Pharmacists Concerning Pharmacogenetics

et al. 2022

View full text Add to dashboard Cite

Background: Pharmacogenetics (PGx) is an important component of personalized medicine that has the potential to improve medicines’ effectiveness and safety. However, despite progress in technology and availability, PGx testing application into patient-care in Eastern Europe countries, has been slow.Objectives: Our aim was to describe knowledge and attitudes of Romanian pharmacists concerning PGx, and identify potential factors limiting PGx implementation.Method: An anonymous, web-based questionnaire was distributed to Romanian pharmacists registered in the National Pharmacists’ Association (NPA) via an official e-mail sent by NPA representatives.Results: A total of 1,058 pharmacists completed the questionnaires, resulting in a response rate of 7.6%. Pharmacists were predominantly female (90.1%), younger than 49 years (87.5%) and mostly worked in community pharmacies (80.2%). Most pharmacists (64.8%) had a knowledge score between 30 and 49 points out of 60, and (75.4%) had attitude scores between 9 and 7 out of 10. Attitude and knowledge scores positively correlated.Conclusion: Despite performing fairly well on general questions regarding PGx, Romanian pharmacists may lack in-depth knowledge, which can affect their readiness to discuss PGx information with patients or other healthcare professionals. High pricing was considered an important impediment in PGx implementation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Nation-Wide Survey Assessing the Knowledge and Attitudes of Romanian Pharmacists Concerning Pharmacogenetics

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, combining PGx testing and CMM services, empowered by a unifying clinical decision support system (CDSS) [ 28 ], promises to yield more valuable results by addressing individual patient needs in a more comprehensive fashion than either component can accomplish alone. This broader PGx-enriched comprehensive medication management (PGx + CMM) approach offers the potential to address many of the most pressing problems in prescription management including medication appropriateness, adherence, and adverse reactions in patients [ 29 , 30 ] through direct engagement of pharmacists who are uniquely well-trained and positioned to lead such efforts [ 31 ]. Additionally, this approach helps address practical limitations inherent in payor coverage models, an uncertain regulatory environment, practitioner education, the assessment of meaningful downstream clinical outcomes, as well as a lack of standardized testing and interpretation in a systematic way [ 32 ].…”

Section: Introductionmentioning

confidence: 99%

Real-World Impact of a Pharmacogenomics-Enriched Comprehensive Medication Management Program

Jarvis

Peter

Keogh

et al. 2022

JPM

View full text Add to dashboard Cite

The availability of clinical decision support systems (CDSS) and other methods for personalizing medicine now allows evaluation of their real-world impact on healthcare delivery. For example, addressing issues associated with polypharmacy in older patients using pharmacogenomics (PGx) and comprehensive medication management (CMM) is thought to hold great promise for meaningful improvements across the goals of the Quadruple Aim. However, few studies testing these tools at scale, using relevant system-wide metrics, and under real-world conditions, have been published to date. Here, we document a reduction of ~$7000 per patient in direct medical charges (a total of $37 million over 5288 enrollees compared to 22,357 non-enrolled) in Medicare Advantage patients (≥65 years) receiving benefits through a state retirement system over the first 32 months of a voluntary PGx-enriched CMM program. We also observe a positive shift in healthcare resource utilization (HRU) away from acute care services and toward more sustainable and cost-effective primary care options. Together with improvements in medication risk assessment, patient/provider communication via pharmacist-mediated medication action plans (MAP), and the sustained positive trends in HRU, we suggest these results validate the use of a CDSS to unify PGx and CMM to optimize care for this and similar patient populations.

show abstract

“…Pharmacogenomics can provide valuable pharmacodynamic and pharmacokinetic information that can be used by pharmacists in the assessment and choice of drug therapy [ 19 ]. Pharmacists‘ roles may include the promotion of the optimal use and timing of pharmacogenomic tests, interpretation of the results of such tests, and education of healthcare professionals, patients and the public about the field of pharmacogenomics [ 20 ].…”

Section: Evolution Of the Traditional Role Of The Pharmacist In The P...mentioning

confidence: 99%

Advances in Pharmacy Practice: A Look towards the Future

Atkinson¹

2022

Pharmacy

View full text Add to dashboard Cite

This review looks at the factors that may influence practice in the future. Transformation could occur at 3 levels. Firstly, the traditional profession of the pharmacist as a dispenser of medicines is expanding. Secondly, the pharmacist’s activities are progressing into new healthcare fields. Thirdly, other changes are stimulated by global developments. This review may be helpful for pharmacy and healthcare leaders looking at the future configuration and aims of their pharmacy services.

show abstract

ASHP Statement on the Pharmacist’s Role in Clinical Pharmacogenomics

Cited by 52 publications

References 23 publications

Nation-Wide Survey Assessing the Knowledge and Attitudes of Romanian Pharmacists Concerning Pharmacogenetics

Nation-Wide Survey Assessing the Knowledge and Attitudes of Romanian Pharmacists Concerning Pharmacogenetics

Real-World Impact of a Pharmacogenomics-Enriched Comprehensive Medication Management Program

Advances in Pharmacy Practice: A Look towards the Future

Contact Info

Product

Resources

About